Newpark Fluids Systems Strengthens Executive Leadership and Board to Drive Continued Growth
25.6.2025 21:39:00 CEST | Business Wire | Press Release
Newpark Fluids Systems (“Newpark” or the “Company”), a leading global independent provider of drilling and completion fluids solutions, and SCF Partners (“SCF”) are pleased to announce several key additions to the Company’s executive leadership and Board of Directors. These strategic appointments, along with significant capital investments, including the development of a leading liquid mud facility in West Texas and a new technology center of excellence in Saudi Arabia, underscore Newpark’s commitment to operational excellence, customer value, and accelerated global growth following its acquisition in 2024.
- Nathan Snoke has joined Newpark Fluids Systems as Senior Vice President, Western Hemisphere bringing nearly two decades of predominantly North American oilfield experience to his role, most recently holding operational and commercial leadership positions with Halliburton and Flotek. He has worked across every major U.S. shale play—from the Rockies and Permian to the Marcellus and Haynesville—developing a deep understanding of basin-specific challenges and customer needs.
In addition to this key executive hire, Newpark has expanded its Board of Directors with the following senior industry leaders:
- Robert West – Former CEO of Anchor Drilling Fluids, Robert brings over 50 years of leadership in the oil and gas industry. During his tenure at Anchor, he guided the company from $25 million to nearly $500 million in revenue, overseeing significant growth and strategic acquisitions.
- W. Quentin Dyson – Most recently Senior Vice President of Operations at Southwestern Energy, Quentin brings 30+ years of experience leading engineering and field operations across drilling, completions, and integrated services. Quentin also held senior roles at EP Energy, BP, and Schlumberger.
- Richard Barker – EVP and CFO at Noble Corporation, Richard has a deep financial and strategic background from his 15-year investment banking career at Moelis & Company and JPMorgan.
David Paterson, CEO of Newpark Fluids Systems, commented,
"We are thrilled to welcome Nathan, Robert, Quentin, and Richard to the Newpark team. Each brings a unique set of skills and experience that perfectly complements our strategy for expansion, innovation, customer alignment and long-term value creation in both domestic and international markets . Their leadership will play a key role in shaping our next chapter of growth."
“Newpark has long been a global leader in drilling and completion fluids, known for its technical strength, customer focus, and operational reliability. These new leaders, coupled with our strategic infrastructure investments, will deepen our capabilities and position us to grow with our customers—across established basins and in emerging markets.”
— Deviyani Misra-Godwin, Managing Director at SCF Partners and Board Member, Newpark Fluids Systems
About Newpark Fluids Systems
Newpark Fluids Systems is a leading provider of drilling and completion fluids solutions, serving oil and gas operators across the globe with a rapidly growing footprint in the geothermal space. With a commitment to performance, sustainability, and innovation, Newpark delivers customized fluid systems and engineering services that maximize drilling efficiency and well productivity. For more information, visit www.newpark.com.
About SCF Partners
Founded in 1989, SCF provides equity capital and strategic growth assistance to build and grow leading energy service, equipment, and technology companies that operate throughout the world. SCF has invested in more than 80 platform companies, made more than 400 additional acquisitions, and also developed 18 publicly listed energy service and equipment companies over its history. The firm is headquartered in Houston, Texas, and has offices in Aberdeen, and Australia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250625058249/en/
Contacts
Media Contact: Kassie Harris, Sr. Mgr. Strategy & Marketing, kharris@newpark.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom